Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 5/20 | 0.41 |
| ▸ | METAP1 | P53582 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CAD | P27708 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12707509 | 1.00 | ALOX15 (0.42) | ALOX15METAP2METAP1ALDH1A1LMNA | |
| SCHEMBL11739657 | 1.00 | ALOX15 (0.42) | ALOX15METAP2METAP1ALDH1A1LMNA | |
| SCHEMBL110808 | 0.86 | ALOX15 (0.42) | ALOX15METAP2METAP1ALDH1A1LMNA | |
| SCHEMBL110806 | 0.86 | ALOX15 (0.42) | ALOX15METAP2METAP1ALDH1A1LMNA | |
| SCHEMBL6304330 | 0.86 | METAP2 (0.45) | ALOX15METAP2METAP1ALDH1A1LMNA | |
| SCHEMBL12438531 | 0.86 | ALOX15 (0.42) | ALOX15METAP2METAP1ALDH1A1LMNA | |
| SCHEMBL110807 | 0.86 | ALOX15 (0.42) | ALOX15METAP2METAP1ALDH1A1LMNA | |
| SCHEMBL12655937 | 0.86 | ALOX15 (0.42) | ALOX15METAP2METAP1ALDH1A1LMNA | |
| SCHEMBL9809030 | 0.86 | METAP2 (0.37) | ALOX15METAP2METAP1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL8853645 | 0.84 | ALOX15 (0.41) | ALOX15METAP2METAP1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424499-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | Abbott Laboratories (US) | 2012-03-07 | — | — | EP | claimed |
| WO-2010127193-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | claimed |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBVIE INC. | 2010-11-04 | — | — | US | claimed |
| US-8927009-B2 | ABT-263 capsule | ABBVIE INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8728516-B2 | Stabilized lipid formulation of apoptosis promoter | ABBVIE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8513243-B2 | ABT-263 crystalline forms | ABBVIE INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8362013-B2 | Salt of ABT-263 and solid-state forms thereof | ABBVIE INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362014-B2 | ABT-263 crystalline forms | ABBVIE INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2515883-A1 | ABT-263 CAPSULE | Abbott Laboratories (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2477972-A1 | ABT-263 CRYSTALLINE FORMS AND SOLVATES FOR USE IN TREATING BCL-2 PROTEIN RELATED DISEASES | Abbott Laboratories (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-2442789-A1 | STABLE NANOPARTICULATE DRUG SUSPENSION | Abbott Laboratories (US) | 2012-04-25 | — | — | EP | disclosed |
| US-7241892-B1 | Hemisynthetic method and new compounds | PHARMA MAR, S.A. (ES) | 2007-07-10 | — | — | US | disclosed |
| US-7241892-B1 | Hemisynthetic method and new compounds | PHARMA MAR, S.A. (ES) | 2007-07-10 | — | — | US | disclosed |
| US-7202361-B2 | Antitumoral ecteinascidin derivatives | PHARMAMAR (ES) | 2007-04-10 | — | — | US | disclosed |
| US-7202361-B2 | Antitumoral ecteinascidin derivatives | PHARMAMAR (ES) | 2007-04-10 | — | — | US | disclosed |
| US-5262436-A | Administering; enzyme inhibitor | SCHERING CORPORATION (US) | 1993-11-16 | — | — | US | disclosed |
| EP-0566157-A1 | Neutral metalloendopeptidase inhibitors in the treatment of hypertension | SCHERING CORPORATION (US) | 1993-10-20 | — | — | EP | disclosed |
| US-4929641-A | DIURETICS, ANGIOTENSIN CONVERTING ENZYMES | SCHERING CORPORATION (US) | 1990-05-29 | — | — | US | disclosed |
| US-4801609-A | Mercapto-acylamino acid antihypertensives | SCHERING CORPORATION (US) | 1989-01-31 | — | — | US | disclosed |
| EP-0254032-A2 | Neutral metalloendopeptidase inhibitors in the treatment of hypertension | SCHERING CORPORATION (US) | 1988-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | BCL2, BAX, BCOR | ALOX15 615/4885METAP2 4253/4885METAP1 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.